Ekrem Yavuz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ekrem Yavuz has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Sitki Tuzlali
Tuzlali Pathology Laboratory Istanbul Türkiye
4 shared publications - Hasan Karanlik
Department of Surgical Oncology, Istanbul University, Institute of Oncology, Istanbul, Turkiye; SENATURK Senology Academy, Istanbul, Turkiye
3 shared publications - Vahit Ozmen
Department of Surgery, Head of Breast Surgery Unit Istanbul Florence Nightingale Hospital Istanbul Türkiye
3 shared publications - Ahmet Serkan Ilgun
Specialist Breast and General Surgeon, Department of General and Vascular Surgery, Mater Dei Hospital, St. Paul’s Bay, Malta
2 shared publications - Cetin Ordu
Department of Medical Oncology, Gayrettepe Florence Nightingale Hospital, Istanbul, Turkey
2 shared publications - Filiz Çelebi
Yeditepe Univ, Fac Med, Dept Radiol, Istanbul, Turkiye
2 shared publications
Latest Publications
- Open Access
- 15 September 2025
- Published by Anatolian Current Medical Journal in Anatolian Current Medical Journal
- Vol. 7 (5) , 623-629
CD1a expressionin Her2-positive breast carcinoma tissues and its prognostic implications
Aims: Dendritic cells are key players in initiating the primary immune response. Many studies have investigated the role of antigen-presenting cells in breast carcinoma, revealing associations between dendritic cell density, their spatial distribution within the tumor, and prognosis. CD1a is a glycosylated type I transmembrane protein that is frequently used as a dendritic cell marker in human tumors. This study aims to detect CD1a expression using immunohistochemical methods in a cohort of HER2-overexpressing breast carcinoma patients. It also analyzes the correlation of CD1a expression with prognostic parameters and overall survival outcomes. Methods: Patient records of individuals diagnosed with invasive breast carcinoma between 2003 and 2009 were retrieved from the digital pathology archive of İstanbul University İstanbul Faculty of Medicine Pathology Department. From this dataset, 48 cases were selected based on the following inclusion criteria: HER2 positivity confirmed. We applied cd1a immunohistochemically to all of these cases and compared the staining with prognostic data. Results: Any level of CD1a positivity was considered when evaluating the association between CD1a expression and survival/ prognostic factors. No statistically significant relationship was found between CD1a positivity and age, tumor size, lymph node involvement, or recurrence. No correlation was identified between CD1a positivity/negativity and the neoadjuvant status of the tumour. However, a significant association was observed between nuclear grade and CD1a positivity. No statistical correlation was found between 5-year total and disease-free survival and CD1a staining. Conclusion: Considering that HER2-positive tumors account for only 25–30% of breast carcinomas, our study focused on a particular and homogeneous patient group. A lower survival rate was expected because HER2 positivity is a known poor prognostic factor, and our cohort consisted of non-early-stage cases. Therefore, while a proportional relationship between CD1a positivity and survival was observed in HER2-positive cases, statistical significance was not achieved. Future studies should include larger patient populations or more heterogeneous cohorts in terms of prognostic features to obtain more conclusive results. In our study, CD1a positivity was significantly associated only with higher nuclear grade.
- 15 September 2025
- Published by Anatolian Current Medical Journal in Anatolian Current Medical Journal
- Vol. 7 (5) , 623-629
Open AccessCD1a expressionin Her2-positive breast carcinoma tissues and its prognostic implications
Aims: Dendritic cells are key players in initiating the primary immune response. Many studies have investigated the role of antigen-presenting cells in breast carcinoma, revealing associations between dendritic cell density, their spatial distribution within the tumor, and prognosis. CD1a is a glycosylated type I transmembrane protein that is frequently used as a dendritic cell marker in human tumors. This study aims to detect CD1a expression using immunohistochemical methods in a cohort of HER2-overexpressing breast carcinoma patients. It also analyzes the correlation of CD1a expression with prognostic parameters and overall survival outcomes. Methods: Patient records of individuals diagnosed with invasive breast carcinoma between 2003 and 2009 were retrieved from the digital pathology archive of İstanbul University İstanbul Faculty of Medicine Pathology Department. From this dataset, 48 cases were selected based on the following inclusion criteria: HER2 positivity confirmed. We applied cd1a immunohistochemically to all of these cases and compared the staining with prognostic data. Results: Any level of CD1a positivity was considered when evaluating the association between CD1a expression and survival/ prognostic factors. No statistically significant relationship was found between CD1a positivity and age, tumor size, lymph node involvement, or recurrence. No correlation was identified between CD1a positivity/negativity and the neoadjuvant status of the tumour. However, a significant association was observed between nuclear grade and CD1a positivity. No statistical correlation was found between 5-year total and disease-free survival and CD1a staining. Conclusion: Considering that HER2-positive tumors account for only 25–30% of breast carcinomas, our study focused on a particular and homogeneous patient group. A lower survival rate was expected because HER2 positivity is a known poor prognostic factor, and our cohort consisted of non-early-stage cases. Therefore, while a proportional relationship between CD1a positivity and survival was observed in HER2-positive cases, statistical significance was not achieved. Future studies should include larger patient populations or more heterogeneous cohorts in terms of prognostic features to obtain more conclusive results. In our study, CD1a positivity was significantly associated only with higher nuclear grade.
- Open Access
- 4 September 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (4) , 333-338
Accuracy of Intraoperative Sentinel Lymph Node Evaluation by Imprint Cytology in Breast Cancer: A 12-Year Single Center Experience With 2,528 Patients
Accuracy of Intraoperative Sentinel Lymph Node Evaluation by Imprint Cytology in Breast Cancer: A 12-Year Single Center Experience With 2,528 Patients - European Journal of Breast Health
- 4 September 2025
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 21 (4) , 333-338
Open AccessAccuracy of Intraoperative Sentinel Lymph Node Evaluation by Imprint Cytology in Breast Cancer: A 12-Year Single Center Experience With 2,528 Patients
Accuracy of Intraoperative Sentinel Lymph Node Evaluation by Imprint Cytology in Breast Cancer: A 12-Year Single Center Experience With 2,528 Patients - European Journal of Breast Health
- Open Access
- 14 April 2025
- Published by Wiley in World Journal of Surgery
- Vol. 49 (6) , 1396-1405
Vitamin D Supplementation During Neoadjuvant Chemotherapy for Breast Cancer Improves Pathological Complete Response: A Prospective Randomized Clinical Trial
Introduction: Achieving a pCR serves as a biomarker indicating enhanced overall survival for breast cancer patients undergoing NST. Vitamin D enhances the antitumor effect of chemotherapeutics as demonstrated in cancer cells and animal models. In this prospective randomized clinical study, we aim to investigate the effect of oral vitamin D supplementation during neoadjuvant systemic therapy (NST) on pathologic complete response (pCR). Methods: Between June 2019 and June 2023, an oral form of 50,000 IU vitamin D3 (cholecalciferol) replacement was administered once a week during NST for the study group. Results: There were 114 (50.2%) cases in the study group and 113 (49.8%) in the control group (totally 227 cases). Factors that positively influenced pCR were higher clinical T stage, higher AJCC clinical stage, Estrogen receptor negativity, progesterone receptor negativity, human epidermal growth factor receptor 2 positivity, high Ki‐67 expression (≥ 20%), hormone negative molecular subtypes, and vitamin D intake in univariate analysis. In the multivariate analysis, factors significantly affecting pCR were vitamin D intake (OR: 2.33, 95% CI 1.20–4.53; p = 0.013), hormone receptor negativity (OR: 2.22, 95% CI 1.11–4.43; p = 0.024), and Ki‐67 ≥ 20% (OR: 3.27, 95% CI 1.03–10.34; p = 0.044). Conclusions: This is the first and only study to compare the effect of oral vitamin D supplementation on pCR during NST. Vitamin D supplementation during NST has a significant effect on pCR in breast cancer patients. Although this effect is not significant for axillary pCR, there is an almost significant correlation. Trial Registration: ClinicalTrials.gov (Identifier: NCT03986268)
- 14 April 2025
- Published by Wiley in World Journal of Surgery
- Vol. 49 (6) , 1396-1405
Open AccessVitamin D Supplementation During Neoadjuvant Chemotherapy for Breast Cancer Improves Pathological Complete Response: A Prospective Randomized Clinical Trial
Introduction: Achieving a pCR serves as a biomarker indicating enhanced overall survival for breast cancer patients undergoing NST. Vitamin D enhances the antitumor effect of chemotherapeutics as demonstrated in cancer cells and animal models. In this prospective randomized clinical study, we aim to investigate the effect of oral vitamin D supplementation during neoadjuvant systemic therapy (NST) on pathologic complete response (pCR). Methods: Between June 2019 and June 2023, an oral form of 50,000 IU vitamin D3 (cholecalciferol) replacement was administered once a week during NST for the study group. Results: There were 114 (50.2%) cases in the study group and 113 (49.8%) in the control group (totally 227 cases). Factors that positively influenced pCR were higher clinical T stage, higher AJCC clinical stage, Estrogen receptor negativity, progesterone receptor negativity, human epidermal growth factor receptor 2 positivity, high Ki‐67 expression (≥ 20%), hormone negative molecular subtypes, and vitamin D intake in univariate analysis. In the multivariate analysis, factors significantly affecting pCR were vitamin D intake (OR: 2.33, 95% CI 1.20–4.53; p = 0.013), hormone receptor negativity (OR: 2.22, 95% CI 1.11–4.43; p = 0.024), and Ki‐67 ≥ 20% (OR: 3.27, 95% CI 1.03–10.34; p = 0.044). Conclusions: This is the first and only study to compare the effect of oral vitamin D supplementation on pCR during NST. Vitamin D supplementation during NST has a significant effect on pCR in breast cancer patients. Although this effect is not significant for axillary pCR, there is an almost significant correlation. Trial Registration: ClinicalTrials.gov (Identifier: NCT03986268)
- 26 August 2022
- Published by Taylor & Francis in Future Oncology
- Vol. 18 (29) , 3289-3298
The effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes in patients with breast cancer
Aim: This study investigated the effect of neoadjuvant chemotherapy (NAC) on stromal tumor-infiltrating lymphocytes (sTILs) and their treatment response. Materials & methods: One hundred fifteen pa... Plain language summary New studies have shown that the tumor microenvironment is critical in tumor behavior. Immune cells surrounding tumor cells are the main components of the tumor microenvironme...
- 26 August 2022
- Published by Taylor & Francis in Future Oncology
- Vol. 18 (29) , 3289-3298
The effect of neoadjuvant chemotherapy on tumor-infiltrating lymphocytes in patients with breast cancer
Aim: This study investigated the effect of neoadjuvant chemotherapy (NAC) on stromal tumor-infiltrating lymphocytes (sTILs) and their treatment response. Materials & methods: One hundred fifteen pa... Plain language summary New studies have shown that the tumor microenvironment is critical in tumor behavior. Immune cells surrounding tumor cells are the main components of the tumor microenvironme...
- 6 December 2018
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 27 (4) , 437-440
Cystic Anastomosing Hemangioma of the Ovary: A Case Report With Immunohistochemical and Ultrastructural Analysis
In this article, we present a case of anastomosing hemangioma that shows cystic change. The tumor was a unilocular cystic lesion consisting of 2 distinct layers. The inner layer was composed of a proliferation of capillary-sized blood vessels resembling red pulp of the spleen. The outer layer was composed of stromal cells that resembled Leydig or steroid cell tumor of the ovary. An immunohistochemical examination confirmed endothelial and stromal characteristics of the layers, respectively. An ultrastructural analysis revealed absence of Reinke crystalloids in the stromal cells. We conclude that anastomosing hemangioma may rarely arise from the ovary as a cystic tumor and may be accompanied with luteinization of stromal cells.
- 6 December 2018
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 27 (4) , 437-440
Cystic Anastomosing Hemangioma of the Ovary: A Case Report With Immunohistochemical and Ultrastructural Analysis
In this article, we present a case of anastomosing hemangioma that shows cystic change. The tumor was a unilocular cystic lesion consisting of 2 distinct layers. The inner layer was composed of a proliferation of capillary-sized blood vessels resembling red pulp of the spleen. The outer layer was composed of stromal cells that resembled Leydig or steroid cell tumor of the ovary. An immunohistochemical examination confirmed endothelial and stromal characteristics of the layers, respectively. An ultrastructural analysis revealed absence of Reinke crystalloids in the stromal cells. We conclude that anastomosing hemangioma may rarely arise from the ovary as a cystic tumor and may be accompanied with luteinization of stromal cells.
- 29 June 2018
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 14 (3) , 160-165
Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study
Objective: As patients with increased human epidermal growth factor receptor (HER2) overexpression are more likely to benefit from trastuzumab treatment, the accuracy of HER2 receptor status in breast cancer patients is significant for appropriate disease management. However, this assessment is not harmonized and results may be highly variable between centers. The aim of this study was to investigate the degree of interlaboratory variability in the results of HER2 expression reported by 5 participating centers and to assess the concordance between these centers and a reference laboratory. Materials and Methods: A total of 30 breast cancer samples were tested and scored for HER2 expression using immunohistochemical method in 5 centers from Turkey and in a reference laboratory from Netherlands (Academic Medical Center, Amsterdam). All the participating centers had an experience of more than 10 years regarding the HER2 testing. The results were compared both among the centers and with the reference laboratory. Results: When the concordance of participating centers and the reference laboratory was evaluated regarding negative (0-1+), equivocal 2(+) and positive 3(+) classification of HER2 immunostaining, the highest concordance was found in Center-A, and the lowest in Center-C (Kendall's tau-b concordance coefficient 0.911 and 0.724, respectively). The concordance of the centers with reference laboratory was 80.0% both in equivocal and positive samples, while it increased up to 91.8% in negative samples. Conclusions: This study showed that in general there is sufficiently good agreement between the reference laboratory and the participating centers for immunohistochemical HER2 assessment.
- 29 June 2018
- Published by Galenos Yayinevi in European Journal of Breast Health
- Vol. 14 (3) , 160-165
Immunohistochemical HER2 Status Evaluation in Breast Cancer Pathology Samples: A Multicenter, Parallel-Design Concordance Study
Objective: As patients with increased human epidermal growth factor receptor (HER2) overexpression are more likely to benefit from trastuzumab treatment, the accuracy of HER2 receptor status in breast cancer patients is significant for appropriate disease management. However, this assessment is not harmonized and results may be highly variable between centers. The aim of this study was to investigate the degree of interlaboratory variability in the results of HER2 expression reported by 5 participating centers and to assess the concordance between these centers and a reference laboratory. Materials and Methods: A total of 30 breast cancer samples were tested and scored for HER2 expression using immunohistochemical method in 5 centers from Turkey and in a reference laboratory from Netherlands (Academic Medical Center, Amsterdam). All the participating centers had an experience of more than 10 years regarding the HER2 testing. The results were compared both among the centers and with the reference laboratory. Results: When the concordance of participating centers and the reference laboratory was evaluated regarding negative (0-1+), equivocal 2(+) and positive 3(+) classification of HER2 immunostaining, the highest concordance was found in Center-A, and the lowest in Center-C (Kendall's tau-b concordance coefficient 0.911 and 0.724, respectively). The concordance of the centers with reference laboratory was 80.0% both in equivocal and positive samples, while it increased up to 91.8% in negative samples. Conclusions: This study showed that in general there is sufficiently good agreement between the reference laboratory and the participating centers for immunohistochemical HER2 assessment.
- 1 November 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (11) , S89
211. Dismal prognosis in metaplastic breast cancer due to the aggressive tumour biology
- 1 November 2014
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 40 (11) , S89
211. Dismal prognosis in metaplastic breast cancer due to the aggressive tumour biology
- 1 September 2011
- Published by S. Karger AG in Oncology
- Vol. 81 (1) , 30-38
Clinical and Pathological Features of Breast Cancer Associated with the Pathological Complete Response to Anthracycline-Based Neoadjuvant Chemotherapy
Objective: Patients with breast cancer with a pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) have a better prognosis than patients with residual disease. The aim of the current study was to identify predictors of pCR. Methods: This retrospective study included 388 patients treated with anthracycline-based NAC. Clinicopathological parameters were compared between the patients with and without pCR in breast and axilla. Results: Treatment consisted of FAC/FEC in 230 patients (59%), TAC in 39 (10%) patients and AC followed by docetaxel in 119 (31%). In all, 36 (9.3%) patients had pCR. In univariate analysis, age, tumor size, lymph node involvement, tumor grade (p = 0.077, n = 265), ER and HER-2 status (n = 213), lymphovascular invasion (LVI), type of chemotherapy and taxane-containing chemotherapy were associated with pCR. In multivariate analysis, ER negativity (p = 0.003), the absence of LVI (p = 0.009) and taxane-containing NAC (p = 0.026) were found to be significant indicators of pCR. Median follow-up time was 69 months. Progression-free survival was significantly improved in patients achieving pCR (p = 0.001). Conclusions: pCR is associated with a better outcome regardless of clinical and pathological parameters in breast cancer patients who receive NAC. The probability of pCR was higher in ER-negative, LVI-negative tumors and in patients treated with sequential taxane-containing chemotherapy.
- 1 September 2011
- Published by S. Karger AG in Oncology
- Vol. 81 (1) , 30-38
Clinical and Pathological Features of Breast Cancer Associated with the Pathological Complete Response to Anthracycline-Based Neoadjuvant Chemotherapy
Objective: Patients with breast cancer with a pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) have a better prognosis than patients with residual disease. The aim of the current study was to identify predictors of pCR. Methods: This retrospective study included 388 patients treated with anthracycline-based NAC. Clinicopathological parameters were compared between the patients with and without pCR in breast and axilla. Results: Treatment consisted of FAC/FEC in 230 patients (59%), TAC in 39 (10%) patients and AC followed by docetaxel in 119 (31%). In all, 36 (9.3%) patients had pCR. In univariate analysis, age, tumor size, lymph node involvement, tumor grade (p = 0.077, n = 265), ER and HER-2 status (n = 213), lymphovascular invasion (LVI), type of chemotherapy and taxane-containing chemotherapy were associated with pCR. In multivariate analysis, ER negativity (p = 0.003), the absence of LVI (p = 0.009) and taxane-containing NAC (p = 0.026) were found to be significant indicators of pCR. Median follow-up time was 69 months. Progression-free survival was significantly improved in patients achieving pCR (p = 0.001). Conclusions: pCR is associated with a better outcome regardless of clinical and pathological parameters in breast cancer patients who receive NAC. The probability of pCR was higher in ER-negative, LVI-negative tumors and in patients treated with sequential taxane-containing chemotherapy.
- 1 April 2001
- Published by Wiley in Pathology International
- Vol. 51 (4) , 305-307
Hamartomatous endocervical polyp with heterologous mesenchymal tissue
We present an endocervical polyp with heterologous elements. Although a few neoplastic cervical lesions with cartilaginous and adipocytic heterologous tissue have been reported, an endocervical polyp with heterologous cartilage and adipose tissue has not been reported before our case. The patient was a 33‐year‐old woman who presented with abnormal uterine bleeding. On physical examination, there were no remarkable findings other than a cervical polyp protruding into the cervical canal. The polyp was removed. Pathological examination revealed an endocervical polyp with typical epithelial features. The stroma of the polyp contained mature cartilage islands and adipose tissue. There were also many thick‐walled vascular structures. Neither stromal periglandular condensation nor atypia was found. Mitotic figures were not observed. Arteriolar structures did not contain internal elastic lamina. In our opinion, these pathological findings are all consistent with a hamartomatous lesion rather than with a true neoplasm.
- 1 April 2001
- Published by Wiley in Pathology International
- Vol. 51 (4) , 305-307
Hamartomatous endocervical polyp with heterologous mesenchymal tissue
We present an endocervical polyp with heterologous elements. Although a few neoplastic cervical lesions with cartilaginous and adipocytic heterologous tissue have been reported, an endocervical polyp with heterologous cartilage and adipose tissue has not been reported before our case. The patient was a 33‐year‐old woman who presented with abnormal uterine bleeding. On physical examination, there were no remarkable findings other than a cervical polyp protruding into the cervical canal. The polyp was removed. Pathological examination revealed an endocervical polyp with typical epithelial features. The stroma of the polyp contained mature cartilage islands and adipose tissue. There were also many thick‐walled vascular structures. Neither stromal periglandular condensation nor atypia was found. Mitotic figures were not observed. Arteriolar structures did not contain internal elastic lamina. In our opinion, these pathological findings are all consistent with a hamartomatous lesion rather than with a true neoplasm.